Luprolide Acetate (Lupron®, Eligard®)

BCommon name: Luprolide Acetate
Brand name: Lupron®, Eligard®
 

What is Luprolide Acetate?

Luprolide Acetate is a hormonal therapy medication that is used in the palliative treatment of advanced prostate cancer. It works by slowing or stopping the production of testosterone to stop or slow prostate cancer cells from growing and reproducing.
 

How is Luprolide Acetate administered?

Luprolide Acetate is administered by subcutaneous injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received luprolide acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast tenderness
  • Decreased libido
  • Diarrhea
  • Fatigue
  • Headaches
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Osteoporosis (weakened bones)
  • Weight gain
 

 Is Luprolide Acetate covered in my province or territory?

Luprolide acetate (Eligard®) is covered by all provincial/territorial drug programs.

​Luprolide acetate (Lupron®​) is covered by provincial drug programs in:
  • Alberta​
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Quebec
  • Saskatchewan
​Luprolide acetate (Lupron®) is not covered by provincial drug programs in:
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Yukon
 

Last Reviewed: July 2017








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive